United Therapeutics (NASDAQ:UTHR) Sees Unusually-High Trading Volume – Time to Buy?

United Therapeutics Co. (NASDAQ:UTHR) shares saw an uptick in trading volume on Thursday . 233,537 shares were traded during trading, a decline of 23% from the previous session’s volume of 301,818 shares.The stock last traded at $353.33 and had previously closed at $354.18.

Wall Street Analyst Weigh In

UTHR has been the subject of several research reports. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Stock Performance

The stock has a market capitalization of $15.85 billion, a P/E ratio of 15.58, a PEG ratio of 0.92 and a beta of 0.57. The company’s fifty day simple moving average is $363.80 and its two-hundred day simple moving average is $357.66.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. The trade was a 17.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $407.32, for a total transaction of $6,109,800.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 128,838 shares of company stock valued at $47,960,356. Insiders own 11.90% of the company’s stock.

Institutional Trading of United Therapeutics

Several large investors have recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics during the fourth quarter worth about $25,000. USA Financial Formulas acquired a new position in shares of United Therapeutics in the 3rd quarter valued at approximately $33,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $82,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.